The early survival benefit of endovascular aneurysm repair (EVAR) over open surgery has resulted in a gradual paradigm shift, with the former progressively becoming the preferred strategy for treatment of patients with aortic abdominal aneurysms (AAAs). [1] [2] [3] The main drawback of EVAR remains the durability of the procedure, with frequent need of secondary intervention for continued success. 2, [4] [5] [6] [7] To assess treatment failure and ultimately prevent death from rupture, intensive life-long postoperative surveillance strategies are recommended, which include at least annual computed tomography angiography (CTA), duplex ultrasound (DUS) imaging, abdominal radiography, or a combination of these. 8 Intensive image follow-up strategies are not innocuous, however. Contrast-induced nephropathy and radiation exposure are worrisome factors when CTA is used as the preferred strategy. 9, 10 Alternatively, DUS imaging is laborious, window and operator dependent, and requires intravenous contrast to obtain comparable results. 11 With both imaging techniques, examinations and subsequent followup visits are costly and involve significant resource allocation, which is only justifiable if patients are at risk of complications. Preoperative risk factors for EVAR-related complications, especially anatomic risk factors, have been studied extensively, with fairly consistent results. [12] [13] [14] [15] However, complications may ensue even in patients with anatomic suitability. This additional risk may result from intraoperative variables or vessel-graft interactions that cannot be evaluated beforehand. The first postoperative CTA may provide valuable additional information and sharpen the predictive capacity for adverse events during follow-up. This, in turn, can help in patient selection, reserving the intensive image follow-up protocols to patients at higher risk.
The purpose of this study was to evaluate the prognostic capacity of the first postoperative scan and identify a subgroup of patients at very low risk of AAA-related adverse events after EVAR.
METHODS

This study complies with the Declaration of Helsinki on research ethics.
Study design. This single-institution retrospective study was based on a prospectively kept database of AAA patients treated by EVAR since 2000 at Erasmus University Medical Center, Rotterdam, The Netherlands.
Patient population. From January 2000 until December 2011, 449 patients with aortoiliac aneurysms were treated at our institution. For this study, only AAA patients treated with the Low-Permeability (LP) Excluder Endoprosthesis (W. L. Gore and Assoc, Flagstaff, Ariz) were included. Exclusion criteria were previous abdominal aortic surgery or infectious aortic pathology. Patients treated until December 2007 were also included in a recently published study aimed at long-term results and morphologic analysis. 16 All patients were assessed preoperatively using CTA and entered the institutional follow-up protocol that included an early postoperative CTA (typically before hospital discharge), a CTA at 6 months and 1 year, and then CTAs yearly thereafter.
Since 2007, the 6-month examination has been waived and CTA surveillance replaced by DUS imaging in selected patients considered at lower risk according to the treating physician's expectations in concurrence with the Clinical Practice Guidelines of the European Society for Vascular Surgery. 8 Also, DUS imaging or noncontrast CTs were performed as an alternative to CTA in patients with impaired renal function.
Preoperative baseline characteristics included age, sex, American Society of Anesthesiologists classification, and anatomic details. Intraoperative details were obtained from operative records and included all intraoperative complementary procedures. Subsequent information was obtained from patient records, and all AAA-related complications and secondary interventions were noted. Cause of death was obtained for patients who died during follow-up.
Image acquisition and analysis. CTA image acquisition was performed according to institutional protocols for EVAR using a 16-slice or 64-slice Brilliance CT scanner (Philips Medical Systems, Best, The Netherlands). Per protocol, collimation is 16 mm Â 1.5 mm or 64 mm Â 0.6 mm, and pitch is 1.15 or 1.2, for 16-slice and 64-slice, respectively. Field of view is the entire abdomen, and the window is set at 350/150 with an increment of 1.0 mm. Radiation parameters are 120 kVp and 150 mA. Intravenous nonionic iodixanol contrast (Visipaque 320; GE Healthcare, Buchler GmbH & Co KG, Braunschweig, Germany) is administered at a dose of 120 mL, using bolus triggering in the juxtadiaphragmatic descending aorta at a threshold of 100 Hounsfield units over the baseline. Detailed preoperative and postoperative measurements were available in our institutional database.
In addition, all first postoperative CTA were reanalyzed using manually generated center lumen line reconstructions of the proximal and distal sealing zones using postprocessing 3Mensio Vascular 4.2 software (3Mensio Medical Imaging BV, Bilthoven, The Netherlands). For the proximal seal, markers were placed in the center of the lumen using axial slices starting at the superior mesenteric artery and at every 2 mm progressing downward until the flow divider. For the distal seal, markers were placed starting distal to the end of the endograft limb and progressing upward until the aortic bifurcation. The sealing length was considered to be the distance where the entire circumference of the aortic and iliac vessel walls and the endograft are completely adjacent. This can be easily verified using the reconstructed axial slices and the distance measured in the stretched-view window (Fig 1) . One vascular surgeon with experience in image analysis (F.B.G.) performed all of the measurements.
The duration of each CTA analysis was typically <5 minutes. Intraobserver variability was tested for a sample of 30 patients, with very good agreement (Pearson correlation coefficient, 0.940; P < .001). A second observer (K.v.L.) repeated these measurements, without significant variability (Pearson correlation coefficient. 0.938; P < .001). Bland-Altman plots were created for intraobserver and interobserver variability (Fig 2) .
Definitions. Anatomic suitability was defined according to the instructions for use for the Excluder Endoprosthesis. 17 A patient was considered to have suitable anatomy if all of the following criteria were met: neck diameter, 19 to 28 mm; neck length, >15 mm; thrombus or calcification in <50% of the aortic circumference, and neck angulation <60 . Oversizing was determined retrospectively according to the following formula: (implanted main-body diameter e reference neck diameter in first 15 mm of intrarenal neck)/reference neck diameter in first 15 mm of infrarenal neck. Insufficient oversizing was considered if <10%.
Additional intraoperative procedures were classified as any additional act performed intraoperatively, not part of the standard endograft implantation, such as proximal cuff or giant Palmaz stent placement, or iliac balloon angioplasty or stenting.
Sufficient postoperative seal was considered if a minimum seal length of 10 mm was present proximally and distally. This 10-mm threshold was based on the manufacturer's instructions for use (minimum proximal neck of 15 mm and iliac landing zone of 10 mm) accounting for a margin of error in the proximal deployment of 5 mm. 16 Early postoperative endoleak was considered as type I, II, III, or undetermined endoleaks observed on the first postoperative CTA.
Deployment accuracy was measured as the distance from the lower edge of the lowermost renal artery and the point where the entire circumference of the aortic wall is covered by the endograft. Suboptimal deployment was defined as positioning of the proximal segment markers of the endograft >5 mm below the optimal position, immediately below the lowermost renal artery. Because distance measurements on intraoperative angiography were unreliable, the distance from the lowermost renal to the endograft on the first CTA was used as a surrogate.
Endograft kinking was considered present if some part of the device displayed a sharp angular image >90 , which was retrospectively identified and consensual after examination by two vascular surgeons experienced in EVAR.
Sac growth was defined as an increase in diameter >5 mm compared with the first postoperative examination, according to the reporting standards for EVAR. 18 Inversely, sac shrinkage was considered as a reduction in diameter >5 mm.
AAA-related adverse events were defined as a composite of the following: occurrence of type Ia, type Ib, type III, or undetermined type endoleaks on postoperative examinations, AAA growth >5 mm in diameter during follow-up, migration >10 mm, device failure, AAA-related death, postimplantation AAA rupture, or any AAA-related secondary intervention. 18 End points. The primary study end point was freedom from AAA-related adverse events. Individually, elements of this composite end point were analyzed separately as secondary end points.
Statistical analysis. To assess the importance of different variables obtained from the first postoperative CTA (seal length, presence of endoleak, endograft kinking, and deployment accuracy), univariable Cox regression analysis was performed. The degree of oversizing was also tested as a possible confounder. Significant variables were then entered in a multivariable model to test for interaction and used as selection criteria for inclusion in a high-risk or low-risk group. Baseline and intraoperative characteristics, as well as distribution of events during follow-up, were compared between groups using count and percentages. Categoric variables are presented as count and percentage and were compared with Pearson c 2 tests. Continuous variables are presented as mean and standard deviation and were compared using Student t-tests or are presented as median and interquartile range (IQR) and were compared with Mann-Whitney U tests for nonparametric distributions. A Kaplan-Meier survival estimate was calculated for freedom from AAA-related adverse events. Estimates for low-risk and high-risk groups were compared using the log-rank (Mantel-Cox) test of equality. Differences were considered significant if P < .05. Statistical analysis was performed using IBM SPSS Statistics 20 software (IBM Inc, Chicago, Ill).
RESULTS
From July 2004 to December 2011, 145 AAA patients were treated with the LP Excluder endoprosthesis at our institution. The study excluded 14 patients: seven had previous aortic open reconstruction, three were mycotic aneurysms, two patients with ruptured AAAs died before a postoperative CTA could be performed, and one was treated for traumatic abdominal aortic rupture. Thus, 131 patients were available for analysis.
The follow-up duration of this cohort was a median 4.1 years (IQR, 2.1-6.1; maximum, 8.1 years). During this period, 30 patients (23%) sustained AAA-related adverse events. The median interval between the index operation and the first postoperative CTA was 2.0 days (IQR, 1-9 days) for the low-risk group and 3.5 days (IQR, 2-17 days) for the high-risk group (P ¼ .081). In 10 patients (four in the low-risk group), the CTA was delayed >30 days because of concerns about renal function deterioration.
Univariable analysis of possible risk factors for AAArelated adverse events revealed length of seal <10 mm and presence of endoleak on the first postoperative CTA were significant. These remained significant after multivariable testing (Table I) . These findings were used to divide patients into a low-risk group (proximal and distal seal length $10 mm and no endoleak) and a high-risk group (with insufficient seal or presence of endoleak, or both). Baseline characteristics are detailed in Table II , and the details of inclusion criteria for the high-risk group are presented in Table III. Four patients (3%) in the low-risk group and 26 (19%) in the high-risk group sustained AAA-related adverse events (P < .001) during the follow-up. Four secondary interventions were required in three patients in the lowrisk group, and 31 secondary interventions were required for 23 patients in the high-risk group. Sac growth was observed in two low-risk patients (3%) and in 15 (22%) high-risk patients. No migration or device failure was observed in either group. All AAA-related adverse events are detailed in Table IV. Kaplan-Meier estimates for freedom from AAA-related adverse events were significantly different between the two groups (P < .001, Fig 3) , with 5-year estimates of 98% for the low-risk group and 52% for the high-risk group.
Four patients in the low-risk group sustained AAArelated adverse events: one patient was converted to open repair due to aortic rupture as a consequence of endograft infection, 2.11 years after EVAR. No signs of infection were present in the 2-year CTA, and sac shrinkage was noted. Unlike the previous cases, this operation resulted from an additional investigation prompted by the presence of symptoms and not as a result of an image finding.
One patient was diagnosed with sac growth after 5 years, in the absence of identifiable endoleak, and was treated by relining the endograft. This treatment was unsuccessful in arresting growth, and a type Ib endoleak became evident 1 year later, which was likely the original cause of growth.
One patient required implantation of an iliac extension (nearly 7 years after EVAR) due to progression of disease and loss of distal seal length.
Lastly, one patient was diagnosed with growth 5 years postoperatively, after a period of shrinkage. This patient was managed conservatively until the end of follow-up. Details of secondary interventions occurring in the lowrisk group are provided in Table V. In the high-risk group, only patients with type I endoleaks, persistent type II endoleaks associated with sac growth, and progressively shorter seal required an intervention.
During the study period, this patient cohort was subject to intensive periodic imaging, mostly using contrasted examinations (Table VI) . For each diagnosis of an AAA-related adverse event over the course of follow-up, 81.7 image examinations had to be performed in the low-risk group and 8.2 in the high-risk group. Imaging was necessary to identify three (75%) of the AAA-related adverse events in the low-risk population, but all occurring after 5 years. In the high-risk group, imaging identified 25 of 26 (96%) of all AAA-related complications.
DISCUSSION
Complications and secondary interventions are frequent after EVAR, and intensive image follow-up is considered mandatory to allow for timely elective treatment of potentially fatal complications that course silently until an acute event occurs, usually rupture or occlusion. 8 Our study suggests, however, that an identifiable subgroup of patients may not benefit from image follow-up for Intensive follow-up imaging may have deleterious effects for patients and health care providers alike. For patients monitored with CTA, radiation exposure and contrast nephropathy are important associated factors that should not be overlooked. 9, 10, 19 Alternatively, DUS imaging is operator-dependent, laborious, and requires intravenous contrast enhancement to achieve comparable sensitivity. 11, 20 Whichever method is used, postoperative image surveillance is costly, requires resource allocation, and may negatively affect a patient's well-being. 21 A recent survey study from the United Kingdom revealed large heterogeneity in surveillance protocols adopted by expert centers. 22 This uncertainty regarding the optimal surveillance program reflects the paucity of evidence regarding risk stratification.
Preoperative anatomic features have been well characterized as risk factors for adverse outcome after EVAR. [12] [13] [14] [15] However, a good proximal or distal landing zone does not guarantee an adequate seal. As an example, it is possible that unintentional low deployment might turn a long proximal neck into a short proximal seal. This is of particular importance in patients with neck angulation, where the distortion of anatomy induced by the deployment systems and parallax error frequently result in oblique positioning of the top stent with a much shorter sealing zone than anticipated. Precise measuring of seal length can be performed quickly and easily using center lumen line reconstruction.
The effect of intraoperative details and on-table imaging on secondary intervention after EVAR has also been investigated. Karthikesalingam et al 23 identified higher risk for patients requiring intraoperative adjuncts and lower risk for those undergoing intraoperative multiplanar CTA. They suggest that these findings may serve as selection criteria for stricter or more "relaxed" imaging follow-up. Like ours, this study relied on the absence of endoleak and adequate sealing zones for prediction of complications. Because intraoperative adjuncts do not always increase risk and on-table CTA is not widely available, we opted to use standard postoperative CTA and postprocessing software for assessment. We believe this approach provides a more applicable and reliable means of monitoring the end result of EVAR procedures.
The concept of using early postoperative information for risk prediction is not novel. Sternbergh et al 21 showed that freedom from endoleak at 1 month was highly predictive of reduced aneurysm-related morbidity. As a result, they proposed a simplified surveillance program that excluded the 6-month examination and replaced CTA by DUS imaging after the first year. Adaptations of this scheme have been widely accepted in clinical practice. 8 Two studies also identified early postoperative endoleaks AAA, Abdominal aortic aneurysm; CI, confidence interval; CTA, computed tomography angiography; HR, hazard ratio. (25) as risk factors for adverse outcome. 24, 25 Stratifying risk on the basis of absence of endoleak and adequate seal zones on the first postoperative CTA is a less specific but more sensitive method than using endoleak presence alone, as our study demonstrates.
A proportion of patients in our study were considered high risk due to identification of a type II endoleak. If detected, these mandate intensive image surveillance because of the risk of sac growth and, ultimately, rupture. [26] [27] [28] Detection of these endoleaks using CTA is relatively insensitive, however, as demonstrated by studies using magnetic resonance angiography and blood-pool agents. 29, 30 Despite this limitation, a much higher proportion of patients progress to sac growth when type II endoleaks are detected This suggests that the method is still applicable as a predictor. 31 Also, specificity of type II endoleak detection has been questioned, because many are reportedly misinterpreted type I or III endoleaks. 32 This adds strength to the argument of including type II endoleaks as a criterion for high-risk inclusion.
Within the first 5 years, only one AAA-related adverse event occurred in the low-risk group. [33] [34] [35] This complication resulted from infection, which was not evident on routine CTAs. As such, for our low-risk patient group, the extensive follow-up did not seem to add significant benefit up to 5 years. After 5 years, three additional events occurred in low-risk patients. Two had progressively shortened distal sealing caused by iliac dilatation. The progression of disease can be expected many years after EVAR, 36 and continued surveillance in patients with a prolonged life expectancy is still obligatory, just like in open surgery. The last patient was identified as having sac growth after a period of shrinkage. The cause of growth could not be determined, and the patient remained under close surveillance. 37 In the low-risk group, 82 image examinations had to be performed for every identified AAA-related adverse event. A cost-benefit analysis is beyond the scope of this study, but this alarmingly high rate of examinations required casts doubt on the benefit for patients and must be acknowledged. Dias et al 38 reported similar findings. Over a median of 54 months, <10% of their cohort of 279 patients actually benefited from CTA surveillance. 38 Most secondary interventions performed were preventive (preceding complications), even in high-risk patients. Of 31 interventions, only six patients had a demonstrated type 1 endoleak, and no ruptures occurred. Moreover, all secondary procedures in the high-risk group were elective. These findings, in line with previously published data on outcome of secondary interventions, 39 reinforce the importance of continued image surveillance for this group.
The results of this study suggest that a risk-stratified postoperative surveillance protocol could be followed for patients treated with the Excluder endoprosthesis (Fig 4) . In high-risk patients, standard annual CTA is advised, with DUS imaging an alternative for selected patients with impaired renal function or favorable sac remodeling. For low-risk patients, imaging up to 5 years would only be performed upon clinical suspicion and not for surveillance purposes. This way, the follow-up strategy for low-risk EVAR patients would not differ significantly from the current practice for open surgical patients. Beyond 5 years, annual CTA or DUS imaging seem advisable due to the risk of late complications as a result of disease progression. Because this is only a preliminary study, this proposed scheme should not be adopted for clinical care before the results can be confirmed in large, prospective series. The retrospective, single-center nature of this study is a limitation that must be acknowledged. Also, selection of patients according to the type of device implanted may be a source of bias and restricts generalization. However, institutional experience with the Excluder endoprosthesis was predominant, and only small numbers of patients were treated with other devices for many years. Moreover, most other devices used before 2008 are no longer commercialized. For the Excluder endograft, on the other hand, there is long-term follow-up, and the device is expected to be available for years to come. From 2008, many patients at our center were treated with a fourthgeneration Endurant endoprosthesis (Medtronic Endovascular, Santa Rosa, Calif). Because follow-up duration is very restricted for this group and extrapolation of future results is impossible, we opted not to include them.
The time between the index operation and the first postoperative CTA was not standardized, which could result in variability. However, this would likely affect both groups equally. The distribution of the time to the first CTA was similar between groups, but the median differed by 1.5 days. This difference did not reach statistical significance, perhaps due to sample size, but should be assumed as a limitation.
Lastly, we cannot ensure that the distance from the lowermost renal artery to the start of the graft remained the same after deployment until the CTA was performed. Because migration is possible during this interval, true deployment accuracy is only an approximation and may not reflect the true intraoperative result in all cases.
CONCLUSIONS
The present study suggests that the first postoperative CTA after EVAR can be used to stratify for the risk of AAA-related adverse events, based on the presence of endoleak and the length of proximal and distal seal. On one hand, roughly half of patients in our population were considered low risk, and imaging surveillance up to 5 years could have been waived, making their follow-up similar to patients undergoing open surgical repair. On the other hand, the results emphasize the need for close surveillance of patients at higher risk of complications. This concept requires validation with larger cohorts and a mixed sample of devices before it leads to a significant change in practice but highlights the necessity to re-evaluate current "onesize-fits-all" surveillance protocols. 
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